Company research
Atrium Therapeutics, Inc.
CIK 2093101
Filing activity
10 filings on record · 4, 10-Q, 8-K, S-8.
About the company
Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food and Drug Administration’s (FDA) recent clearance of its Investigational New Drug (IND) application for ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome, Atrium is advancing its first precision cardiology program into the clinic through the Corventis Phase 1/2 clinical trial. The Company’s proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides and is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to skeletal muscle and applies it for efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. Beyond ATR 1072, the Company’s pipeline includes ATR 1…
Recent filings
4 filing
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Filing attachments
d149126dex991.htm · 8-K · 2026-08-13
EX-99.1 2 d149126dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atrium Therapeutics Reports Second Quarter 2026 Financial Results - IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome - - Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb - SAN DIEGO, August 13, 2026 / PRNewswire/ - Atrium Therapeutics, Inc. (Nasdaq: RNA) (“Atrium,” “Atrium Therapeutics,” or the “Company”), a biopharmaceutical company advanc…
Read attachment ↗d132402dex991.htm · 8-K · 2026-07-14
EX-99.1 2 d132402dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome - ATR 1072 is the company’s first precision cardiology program to enter the clinic -- - Corventis ™ will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease - SAN DIEGO, July 14, 2026 /PRNewswire/ - Atrium Ther…
Read attachment ↗d82207dex991.htm · 8-K · 2026-05-14
EX-99.1 2 d82207dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atrium Therapeutics Reports First Quarter 2026 Financial Results SAN DIEGO, May 14, 2026 / PRNewswire/ - Atrium Therapeutics, Inc. (Nasdaq: RNA) (“Atrium,” “Atrium Therapeutics” or the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate progress followin…
Read attachment ↗